

**Thrombosis Ireland Company Limited by Guarantee**  
**Annual Report and Financial Statements**  
**for the financial year ended 31 March 2024**

**Thrombosis Ireland Company Limited by Guarantee**  
**CONTENTS**

	<b>Page</b>
Directors and Other Information	3
Directors' Report	4 - 5
Directors' Responsibilities Statement	6
Independent Auditor's Report	7 - 8
Appendix to the Independent Auditor's Report	9
Income Statement	10
Statement of Financial Position	11
Reconciliation of Members' Funds	12
Statement of Cash Flows	13
Notes to the Financial Statements	14 - 16
Supplementary Information on Trading Statement	18 - 19

**Thrombosis Ireland Company Limited by Guarantee**  
**DIRECTORS AND OTHER INFORMATION**

<b>Directors</b>	Noel Carberry Niall O'Gorman Gordon Stewart Ann O'Sullivan Lauren Carey (Resigned 1 August 2023)
<b>Company Secretary</b>	Noel Carberry (Appointed 1 August 2023) Lauren Carey (Resigned 1 August 2023)
<b>Company Number</b>	578906
<b>Charity Number</b>	CHY 22021/ CRA 20154240
<b>Business Address</b>	Unit 5 Terenure Enterprise Centre 17 Rathfarnham Road Dublin 6W D6W YW68 Ireland
<b>Auditors</b>	TGS Ireland GBW Limited TGS Ireland GBW Chartered Accountants and Statutory Auditors Westmoreland House Westmoreland Park Dublin D06 DP62
<b>Bankers</b>	Bank of Ireland Rathfarnham Shopping Centre Rathfarnham Dublin 14

# Thrombosis Ireland Company Limited by Guarantee

## DIRECTORS' REPORT

for the financial year ended 31 March 2024

The directors present their report and the audited financial statements for the financial year ended 31 March 2024.

### Principal Activity and Review of the Business

To provide support, education and advocacy for patients with thrombosis. To promote information and national awareness of thrombosis for patients, medical staff and the general public. The provision of testing strips for patients and the provision of self-testing machines.

The Company is limited by guarantee not having a share capital.

There has been no significant change in these activities during the financial year ended 31 March 2024.

### Financial Results

The deficit for the financial year after providing for depreciation amounted to €(26,472) (2023 - €(33,719)).

At the end of the financial year, the company has assets of €38,543 (2023 - €66,111) and liabilities of €3,844 (2023 - €4,940). The net assets of the company have decreased by €(26,472).

### Directors and Secretary

The directors who served throughout the financial year, except as noted, were as follows:

Noel Carberry  
Niall O'Gorman  
Gordon Stewart  
Ann O'Sullivan  
Lauren Carey (Resigned 1 August 2023)

The secretaries who served during the financial year were:

Noel Carberry (Appointed 1 August 2023)  
Lauren Carey (Resigned 1 August 2023)

There were no changes in shareholdings between 31 March 2024 and the date of signing the financial statements.

In accordance with the Constitution, the directors retire by rotation and, being eligible, offer themselves for re-election.

### Future Developments

The company plans to continue its present activities and current trading levels. Employees are kept as fully informed as practicable about developments within the business.

### Post Statement of Financial Position Events

There have been no significant events affecting the company since the financial year-end.

### Auditors

The auditors, TGS Ireland GBW Limited, (TGS Ireland GBW Chartered Accountants) have indicated their willingness to continue in office in accordance with the provisions of section 383(2) of the Companies Act 2014.

### Reserves Policy

The Board of Thrombosis Ireland Company Limited by Guarantee has set a reserves policy which requires:

- Reserves are being maintained at a level which ensures that Thrombosis Ireland Company Limited by Guarantee core activity could continue during a period of unforeseen difficulty.
- A proportion of reserves are maintained in a readily releasable form.

This takes into account:

- Risks associated with income and expenditure being different from that budgeted.
- Planned activity level and potential opportunities.
- The organisation's contractual commitments.

The level of reserves is kept under constant review through ongoing financial reporting and production of annual audited financial statements.

### Statement on Relevant Audit Information

In accordance with section 330 of the Companies Act 2014, so far as each of the persons who are directors at the time this report is approved are aware, there is no relevant audit information of which the statutory auditors are unaware. The directors have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and they have established that the statutory auditors are aware of that information.


**Thrombosis Ireland Company Limited by Guarantee**  
**DIRECTORS' REPORT**

for the financial year ended 31 March 2024

**Accounting Records**


To ensure that adequate accounting records are kept in accordance with sections 281 to 285 of the Companies Act 2014, the directors have employed appropriately qualified accounting personnel and have maintained appropriate computerised accounting systems. The accounting records are located at the company's office at .

Signed on behalf of the board



---

Niall O'Gorman  
Director



---

Noel Carberry  
Director

2 August 2024

# Thrombosis Ireland Company Limited by Guarantee DIRECTORS' RESPONSIBILITIES STATEMENT

for the financial year ended 31 March 2024

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.


Irish company law requires the directors to prepare financial statements for each financial year. Under the law the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the surplus or deficit of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.


The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and surplus or deficit of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014 and enable the financial statements to be readily and properly audited. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Signed on behalf of the board



---

Niall O'Gorman  
Director



---

Noel Carberry  
Director

2 August 2024

# **INDEPENDENT AUDITOR'S REPORT**

## **to the Members of Thrombosis Ireland Company Limited by Guarantee**

### **Report on the audit of the financial statements**

#### **Opinion**

We have audited the financial statements of Thrombosis Ireland Company Limited by Guarantee ('the company') for the financial year ended 31 March 2024 which comprise the Income Statement, the Statement of Financial Position, the Reconciliation of Members' Funds, the Statement of Cash Flows and the related notes to the financial statements, including the summary of significant accounting policies set out in note 2. The financial reporting framework that has been applied in their preparation is Irish Law and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued in the United Kingdom by the Financial Reporting Council.

In our opinion the financial statements:

- give a true and fair view of the assets, liabilities and financial position of the company as at 31 March 2024 and of its deficit for the financial year then ended;
- have been properly prepared in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland"; and
- have been properly prepared in accordance with the requirements of the Companies Act 2014.

#### **Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are described below in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of financial statements in Ireland, including the Ethical Standard for Auditors (Ireland) issued by the Irish Auditing and Accounting Supervisory Authority (IAASA), and the Provisions Available for Audits of Small Entities, in the circumstances set out in note 4 to the financial statements, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### **Conclusions relating to going concern**

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from the date when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

#### **Other Information**

The directors are responsible for the other information. The other information comprises the information included in the annual report other than the financial statements and our Auditor's Report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

#### **Opinions on other matters prescribed by the Companies Act 2014**

In our opinion, based on the work undertaken in the course of the audit, we report that:

- the information given in the Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Directors' Report has been prepared in accordance with applicable legal requirements.

We have obtained all the information and explanations which, to the best of our knowledge and belief, are necessary for the purposes of our audit.

In our opinion the accounting records of the company were sufficient to permit the financial statements to be readily and properly audited and the financial statements are in agreement with the accounting records.

# **INDEPENDENT AUDITOR'S REPORT**

## **to the Members of Thrombosis Ireland Company Limited by Guarantee**

### **Matters on which we are required to report by exception**

Based on the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified any material misstatements in the directors' report.

The Companies Act 2014 requires us to report to you if, in our opinion, the requirements of any of sections 305 to 312 of the Act, which relate to disclosures of directors' remuneration and transactions are not complied with by the Company. We have nothing to report in this regard.

### **Respective responsibilities**

#### **Responsibilities of directors for the financial statements**

As explained more fully in the Directors' Responsibilities Statement set out on page 6, the directors are responsible for the preparation of the financial statements in accordance with the applicable financial reporting framework that give a true and fair view, and for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, if applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the company or to cease operation, or has no realistic alternative but to do so.

#### **Auditor's responsibilities for the audit of the financial statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's Report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is contained in the appendix to this report, located at page 9, which is to be read as an integral part of our report.

#### **The purpose of our audit work and to whom we owe our responsibilities**

Our report is made solely to the company's members, as a body, in accordance with section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an Auditor's Report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume any responsibility to anyone other than the company and the company's members, as a body, for our audit work, for this report, or for the opinions we have formed.

*TGS Ireland GBW*

---

#### **TGS IRELAND GBW LIMITED**

TGS Ireland GBW Chartered Accountants and Statutory Auditors  
Westmoreland House  
Westmoreland Park  
Dublin  
D06 DP62

**2 August 2024**



## **Thrombosis Ireland Company Limited by Guarantee APPENDIX TO THE INDEPENDENT AUDITOR'S REPORT**

### **Further information regarding the scope of our responsibilities as auditor**

As part of an audit in accordance with ISAs (Ireland), we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our Auditor's Report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our Auditor's Report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.


We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

**Thrombosis Ireland Company Limited by Guarantee**  
**INCOME STATEMENT**


for the financial year ended 31 March 2024

	Notes	2024 €	2023 €
Income		95,639	65,162
Expenditure		(122,111)	(98,881)
Deficit for the financial year		<u>(26,472)</u>	<u>(33,719)</u>
Total comprehensive income		<u><u>(26,472)</u></u>	<u><u>(33,719)</u></u>

Approved by the board on 2 August 2024 and signed on its behalf by:



\_\_\_\_\_  
Niall O'Gorman  
Director



\_\_\_\_\_  
Noel Carberry  
Director

**Thrombosis Ireland Company Limited by Guarantee**


**STATEMENT OF FINANCIAL POSITION**

as at 31 March 2024


	Notes	2024 €	2023 €
<b>Fixed Assets</b>			
Tangible assets	7	1,189	1,805
<b>Current Assets</b>			
Debtors	8	935	855
Cash and cash equivalents		36,419	63,451
		37,354	64,306
<b>Creditors: amounts falling due within one year</b>	10	(3,844)	(4,940)
<b>Net Current Assets</b>		33,510	59,366
<b>Total Assets less Current Liabilities</b>		34,699	61,171
<b>Reserves</b>			
Retained surplus		34,699	61,171
<b>Equity attributable to owners of the company</b>		34,699	61,171

The financial statements have been prepared in accordance with the small companies' regime.

Approved by the board on 2 August 2024 and signed on its behalf by:



Niall O'Gorman  
Director



Noel Carberry  
Director

**Thrombosis Ireland Company Limited by Guarantee**  
**RECONCILIATION OF MEMBERS' FUNDS**

as at 31 March 2024

	Retained surplus	Total
	€	€
At 1 April 2022	94,890	94,890
Deficit for the financial year	<u>(33,719)</u>	<u>(33,719)</u>
At 31 March 2023	61,171	61,171
Deficit for the financial year	<u>(26,472)</u>	<u>(26,472)</u>
At 31 March 2024	<u><u>34,699</u></u>	<u><u>34,699</u></u>

**Thrombosis Ireland Company Limited by Guarantee**

**STATEMENT OF CASH FLOWS**

for the financial year ended 31 March 2024

	Notes	2024 €	2023 €
<b>Cash flows from operating activities</b>			
Deficit for the financial year		(26,472)	(33,719)
Adjustments for:			
Depreciation		616	224
		<u>(25,856)</u>	<u>(33,495)</u>
Movements in working capital:			
Movement in debtors		(80)	(780)
Movement in creditors		(1,096)	2,090
		<u>(27,032)</u>	<u>(32,185)</u>
<b>Cash flows from investing activities</b>			
Payments to acquire tangible assets		-	(509)
<b>Net decrease in cash and cash equivalents</b>		<b>(27,032)</b>	<b>(32,694)</b>
<b>Cash and cash equivalents at beginning of financial year</b>		<b>63,451</b>	<b>96,145</b>
<b>Cash and cash equivalents at end of financial year</b>	<b>9</b>	<b>36,419</b>	<b>63,451</b>

# Thrombosis Ireland Company Limited by Guarantee

## NOTES TO THE FINANCIAL STATEMENTS

for the financial year ended 31 March 2024

### 1. General Information

Thrombosis Ireland Company Limited by Guarantee is a company limited by guarantee incorporated and registered in Ireland. The registered number of the company is 578906. The registered office of the company is. The nature of the company's operations and its principal activities are set out in the Directors' Report. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

### 2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

#### Statement of compliance

The financial statements of the company for the financial year ended 31 March 2024 have been prepared on the going concern basis and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" (FRS 102).

#### Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014.

#### Income

Income is comprised of donations and grants. Voluntary income is included in the Income and Expenditure account when the charity is legally entitled to it, its financial value can be quantified with reasonable certainty and there is reasonable certainty of its ultimate receipt. Grants for activities are recognised as income when the related conditions for legal entitlement have been met.

#### Tangible assets and depreciation

Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:

Fixtures, fittings and equipment	-	10% Straight line
Computer equipment	-	20% to 33% Straight line

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

#### Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

#### Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

#### Taxation

The company is exempt from Corporation taxation in respect of its activities. Passive income, if any (such as deposit interest), remains taxable.

## Thrombosis Ireland Company Limited by Guarantee NOTES TO THE FINANCIAL STATEMENTS

for the financial year ended 31 March 2024

### Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Statement of Financial Position date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Income Statement.

### 3. Departure from Companies Act 2014 Presentation

The directors have elected to present an Income and Expenditure Account instead of a Profit and Loss Account in these financial statements as this company is a not-for-profit entity.

### 4. Provisions Available for Audits of Small Entities

In common with many other charitable companies of our size and nature, we use our auditors to assist with the preparation of the financial statements, to prepare and submit returns to the Companies Registration Office and to prepare and file corporation tax returns with Revenue.

5. Operating deficit	2024	2023
	€	€
Operating deficit is stated after charging:		
Depreciation of tangible assets	616	224
	<u>          </u>	<u>          </u>

### 6. Employees

The average monthly number of employees, including directors, during the financial year was 0, (2023 - 0).

### 7. Tangible assets

	Fixtures, fittings and equipment €	Computer equipment €	Total €
<b>Cost</b>			
At 1 April 2023	589	4,462	5,051
	<u>          </u>	<u>          </u>	<u>          </u>
At 31 March 2024	589	4,462	5,051
	<u>          </u>	<u>          </u>	<u>          </u>
<b>Depreciation</b>			
At 1 April 2023	428	2,818	3,246
Charge for the financial year	59	557	616
	<u>          </u>	<u>          </u>	<u>          </u>
At 31 March 2024	487	3,375	3,862
	<u>          </u>	<u>          </u>	<u>          </u>
<b>Net book value</b>			
At 31 March 2024	102	1,087	1,189
	<u>          </u>	<u>          </u>	<u>          </u>
At 31 March 2023	161	1,644	1,805
	<u>          </u>	<u>          </u>	<u>          </u>

8. Debtors	2024	2023
	€	€
Prepayments	935	855
	<u>          </u>	<u>          </u>
9. Cash and cash equivalents	2024	2023
	€	€
Cash and bank balances	36,419	63,451
	<u>          </u>	<u>          </u>

**Thrombosis Ireland Company Limited by Guarantee**  
**NOTES TO THE FINANCIAL STATEMENTS**

for the financial year ended 31 March 2024

10. Creditors	2024	2023
Amounts falling due within one year	€	€
Accruals	<u>3,844</u>	<u>4,940</u>

**11. Status**

The liability of the members is limited.

Every member of the company undertakes to contribute to the assets of the company in the event of its being wound up while they are members, or within one financial year thereafter, for the payment of the debts and liabilities of the company contracted before they ceased to be members, and of the costs, charges and expenses of winding up, and for the adjustment of the rights of the contributors among themselves, such amount as may be required, not exceeding € 2.

**12. Capital commitments**

The company had no material capital commitments at the financial year-ended 31 March 2024.

**13. Events After the End of the Reporting Period**

There have been no significant events affecting the company since the financial year-end.

**14. Approval of financial statements**

The financial statements were approved and authorised for issue by the board of directors on 2 August 2024.



THROMBOSIS IRELAND COMPANY LIMITED BY GUARANTEE

SUPPLEMENTARY INFORMATION

RELATING TO THE FINANCIAL STATEMENTS

FOR THE FINANCIAL YEAR ENDED 31 MARCH 2024

NOT COVERED BY THE AUDITORS REPORT

THE FOLLOWING PAGES DO NOT FORM PART OF THE AUDITED FINANCIAL STATEMENTS

**Thrombosis Ireland Company Limited by Guarantee**  
**SUPPLEMENTARY INFORMATION RELATING TO THE FINANCIAL STATEMENTS**  
**TRADING STATEMENT**  
for the financial year ended 31 March 2024

	Schedule	2024 €	2023 €
Income		95,639	65,162
Gross surplus Percentage		100.0%	100.0%
Overhead expenses	1	(122,111)	(98,881)
<b>Net deficit</b>		<b>(26,472)</b>	<b>(33,719)</b>

**Thrombosis Ireland Company Limited by Guarantee**  
**SUPPLEMENTARY INFORMATION RELATING TO THE FINANCIAL STATEMENTS**  
**SCHEDULE 1 ; OVERHEAD EXPENSES**  
for the financial year ended 31 March 2024

	2024 €	2023 €
<b>Administration Expenses</b>		
Rent payable	9,458	8,735
Insurance	474	449
Printing, postage and stationery	1,914	2,941
Awareness & Patient Support costs	101,076	80,339
Telephone Broadband	673	477
Computer costs	71	547
Travelling and entertainment	3,074	(724)
Bank charges	142	70
General expenses	461	588
Auditor's remuneration	4,152	5,235
Depreciation of tangible assets	616	224
	<u>122,111</u>	<u>98,881</u>